Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
Company profile
Ticker
VCYT
Exchange
Website
CEO
Bonnie Anderson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CALDEROME INC
SEC CIK
Corporate docs
Subsidiaries
Veracyte International Corp. • Veracyte Global, B.V. • Veracyte SD, Inc. • Veracyte Labs SD Corporation • Delight Merger Sub II, LLC • Veracyte SAS • Veracyte Labs VA Corporation ...
IRS number
205455398
VCYT stock data
Analyst ratings and price targets
Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
22 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
10 Feb 23
8-K
Departure of Directors or Certain Officers
14 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Veracyte Announces Third Quarter 2022 Financial Results
2 Nov 22
8-K
Departure of Directors or Certain Officers
11 Aug 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Veracyte Announces Second Quarter 2022 Financial Results
2 Aug 22
Transcripts
VCYT
Earnings call transcript
2022 Q3
2 Nov 22
VCYT
Earnings call transcript
2022 Q2
3 Aug 22
VCYT
Earnings call transcript
2022 Q1
4 May 22
VCYT
Earnings call transcript
2021 Q4
1 Mar 22
VCYT
Earnings call transcript
2021 Q3
10 Nov 21
VCYT
Earnings call transcript
2021 Q2
30 Jul 21
VCYT
Earnings call transcript
2021 Q1
11 May 21
VCYT
Earnings call transcript
2020 Q4
18 Feb 21
VCYT
Earnings call transcript
2020 Q3
2 Nov 20
VCYT
Earnings call transcript
2020 Q3
2 Nov 20
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 155.00 mm | 155.00 mm | 155.00 mm | 155.00 mm | 155.00 mm | 155.00 mm |
| Cash burn (monthly) | 5.29 mm | 1.58 mm | 1.81 mm | 3.42 mm | (no burn) | (no burn) |
| Cash used (since last report) | 14.24 mm | 4.25 mm | 4.86 mm | 9.22 mm | n/a | n/a |
| Cash remaining | 140.76 mm | 150.74 mm | 150.13 mm | 145.78 mm | n/a | n/a |
| Runway (months of cash) | 26.6 | 95.5 | 83.1 | 42.6 | n/a | n/a |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 221 |
| Opened positions | 51 |
| Closed positions | 34 |
| Increased positions | 74 |
| Reduced positions | 70 |
| 13F shares | Current |
|---|---|
| Total value | 1.68 tn |
| Total shares | 76.17 mm |
| Total puts | 8.20 k |
| Total calls | 29.20 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| ARK Investment Management | 8.30 mm | $196.96 bn |
| Vanguard | 6.85 mm | $162.61 bn |
| Wellington Management | 6.64 mm | $157.49 bn |
| BLK Blackrock | 6.53 mm | $155.07 bn |
| STT State Street | 4.16 mm | $98.70 bn |
| Artisan Partners Limited Partnership | 3.76 mm | $89.25 bn |
| CMTDF Sumitomo Mitsui Trust | 3.06 mm | $72.72 bn |
| Nikko Asset Management Americas | 3.06 mm | $72.60 bn |
| ArrowMark Colorado | 2.79 mm | $66.20 bn |
| Fisher Asset Management | 2.09 mm | $49.49 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Mar 23 | Eastham Karin | Common Stock | Sell | Dispose S | No | Yes | 22.7757 | 18,750 | 427.04 k | 23,451 |
| 16 Mar 23 | Eastham Karin | Common Stock | Option exercise | Acquire M | No | Yes | 12.12 | 18,750 | 227.25 k | 42,201 |
| 16 Mar 23 | Eastham Karin | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 12.12 | 18,750 | 227.25 k | 0 |
| 15 Mar 23 | Bonnie H Anderson | Common Stock | Sell | Dispose S | No | Yes | 22.7614 | 34,000 | 773.89 k | 53,967 |
| 15 Mar 23 | Bonnie H Anderson | Common Stock | Option exercise | Acquire M | No | Yes | 5.61 | 34,000 | 190.74 k | 87,967 |
| 15 Mar 23 | Bonnie H Anderson | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 5.61 | 34,000 | 190.74 k | 68,117 |
| 6 Mar 23 | Stapley Marc | Common Stock | Grant | Acquire A | No | No | 0 | 78,044 | 0.00 | 230,899 |
| 6 Mar 23 | Stapley Marc | Stock Option Common Stock | Grant | Acquire A | No | No | 23.73 | 128,869 | 3.06 mm | 128,869 |
| 6 Mar 23 | Annie McGuire | Common Stock | Grant | Acquire A | No | No | 0 | 23,413 | 0.00 | 54,818 |
| 6 Mar 23 | Annie McGuire | Stock Option Common Stock | Grant | Acquire A | No | No | 23.73 | 38,660 | 917.40 k | 38,660 |
News
Needham Maintains Buy on Veracyte, Raises Price Target to $34
23 Feb 23
Veracyte Q4 EPS $(0.05) Beats $(0.15) Estimate, Sales $80.30M Beat $74.91M Estimate
22 Feb 23
Earnings Scheduled For February 22, 2023
22 Feb 23
A Preview Of Veracyte's Earnings
21 Feb 23
Data Published in "The Red Journal" Validate Prognostic Value Of Veracyte's Decipher Prostate Genomic Classifier For Men With High-Risk Prostate Cancer
15 Feb 23
Press releases
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company's Multi-Omics Capabilities and Tools for Biopharma Partners
15 Mar 23
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
11 Mar 23
Veracyte to Participate in Upcoming Investor Conferences
27 Feb 23
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
22 Feb 23
Data Published in "The Red Journal" Validate Prognostic Value of Veracyte's Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
15 Feb 23